- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Media
- Prime Careers Spotlight
- 2024
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- 2025
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Prime Careers Spotlight: March 2026
- Prime Careers Spotlight: April 2026
- Publications
- Cell & Gene Pipeline Outlook
- Climate change: An imprint on health
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Employer Market Insight Reports
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Expert Clinical Network Insights: March 2026
- Expert Clinical Network Insights: May 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- FDA Decisions Expected: April 2026
- FDA Decisions Expected: May 2026
- FDA Decisions Expected: June 2026
- FDA Decisions Expected: July 2026
- FDA Decisions Expected: August 2026
- FDA Decisions Expected: September 2026
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- GLP-1 Pipeline Update: May 2026
- GLP-1 Pipeline Update: August 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- High-Cost Therapy Profile: March 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- Oncology Insights: March 2026
- Oncology Insights: April 2026
- Oncology Insights: May 2026
- Oncology Insights: June 2026
- Oncology Insights: July 2026
- Oncology Insights: August 2026
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- 2026 Medical Pharmacy Trend Report Part 1
- 2026 Medical Pharmacy Trend Report Part 2
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- Spring 2026 Prime Therapeutics Report
- Summer 2026 Prime Therapeutics Report
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- Quarterly Drug Approvals: April 2026
- Quarterly Drug Approvals: July 2026
- Quarterly Drug Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Quarterly Drug Pipeline: April 2026
- Quarterly Drug Pipeline: July 2026
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Trending Topics & Drug Approvals: February 2026
- Trending Topics & Drug Approvals: March 2026
- Trending Topics & Drug Approvals: April 2026
- Trending Topics & Drug Approvals: May 2026
- Trending Topics & Drug Approvals: June 2026
- Trending Topics & Drug Approvals: July 2026
- Trending Topics & Drug Approvals: August 2026
- Virtual reality: An emerging paradigm in health care
- Weight management: A holistic journey
- Research
- Compliance / Legal
- Home
- Who we are
- Read, watch, listen
- Pharmacy
- Home Delivery
- Specialty Pharmacy
- Specialty Pharmacy - Patients
- Care Specialists Program
- Education Center
- Hypercholesterolemia
- Solid organ transplant
- Asthma
- Cystic fibrosis
- Hemophilia
- Hepatitis C
- Human Immunodeficiency Virus (HIV)
- Inflammatory bowel disease
- Osteoporosis
- Multiple Sclerosis
- Oncology (cancer)
- Psoriasis and psoriatic arthritis
- Rheumatoid arthritis
- Rights and responsibilities
- Overcome medicine challenges
- Specialty Pharmacy - Providers
- Patient Forms
- Careers
- Benefits
- Hub + Home
- Medication Therapy Management Internship
- Managed Care Residency Program
- Application Process
- Contact Us
- Newsroom Custom Content
- Media
- Prime Careers Spotlight
- 2024
- Prime Careers Spotlight: September 2024
- Prime Careers Spotlight: October 2024
- Prime Careers Spotlight: November 2024
- 2025
- Prime Careers Spotlight: April 2025
- Prime Careers Spotlight: December 2025
- Prime Careers Spotlight: November 2025
- Prime Careers Spotlight: October 2025
- Prime Careers Spotlight: September 2025
- Prime Careers Spotlight: August 2025
- Prime Careers Spotlight: July 2025
- Prime Careers Spotlight: June 2025
- Prime Careers Spotlight: May 2025
- Prime Careers Spotlight: January 2026
- Prime Careers Spotlight: February 2026
- Prime Careers Spotlight: March 2026
- Prime Careers Spotlight: April 2026
- Publications
- Cell & Gene Pipeline Outlook
- Climate change: An imprint on health
- Clinical Highlights
- Clinical Highlights: September 2024
- Clinical Highlights: October 2024
- Clinical Highlights: November 2024
- Clinical Highlights: December 2024
- Clinical Highlights: January 2025
- Clinical Highlights: February 2025
- Clinical Highlights: March 2025
- Clinical Highlights: April 2025
- Clinical Insights
- 2022 Clinical Insights: Therapeutic Psychedlics: An emerging frontier in mental health
- 2022 Clinical Insights: Virtual reality: An emerging paradigm in healthcare
- Summer 2025 Issue: Clinical Insights – MASH
- Clinical News
- Clinical News
- Clinical News: August 2024
- Clinical News: June 2024
- Clinical News: May 2024
- Clinical News: April 2024
- Drug Approvals
- Drug Approvals Monthly Update: August 2024
- Drug Approvals Monthly Update: June 2024
- Drug Approvals Monthly Update: May 2024
- Drug Approvals Monthly Update: April 2024
- Drug Approvals Monthly Update: March 2024
- Drug Approvals Monthly Update: February 2024
- Drug Approvals Monthly Update: January 2024
- Drug Approvals Quarterly Update
- Drug Approvals Monthly Update: September 2024
- Drug Approvals: October 2024
- Drug Approvals: November 2024
- Drug Approvals: December 2024
- Drug Approvals: January 2025
- Drug Approvals: July 2024
- Drug Approvals: February 2025
- Drug Approvals: March 2025
- Drug Approvals: April 2025
- Employer Market Insight Reports
- Expert Clinical Network Insights
- 2024-2025
- Expert Clinical Network Insights: June 2024
- Expert Clinical Network Insights: April 2024
- Expert Clinical Network Insights: October 2024
- Expert Clinical Network Insights: December 2024
- Expert Clinical Network Insights: March 2025
- Expert Clinical Network Insights: August 2025
- Expert Clinical Network Insights: September 2025
- Expert Clinical Network Insights: December 2025
- Expert Clinical Network Insights: January 2026
- Expert Clinical Network Insights: March 2026
- Expert Clinical Network Insights: May 2026
- FDA Decisions Expected
- 2024-2025
- FDA Decisions Expected: October 2024
- FDA Decisions Expected November 2024
- FDA Decisions Expected: December 2024
- FDA Decisions Expected: January 2025
- FDA Decisions Expected: February 2025
- FDA Decisions Expected: March 2025
- FDA Decisions Expected: April 2025
- FDA Decisions Expected: May 2025
- FDA Decisions Expected: June 2025
- FDA Decisions Expected: July 2025
- FDA Decisions Expected: August 2025
- FDA Decisions Expected: September2025
- FDA Decisions Expected: October 2025
- FDA Decisions Expected: November 2025
- FDA Decisions Expected: December 2025
- FDA Decisions Expected: January 2026
- FDA Decisions Expected: February 2026
- FDA Decisions Expected: March 2026
- FDA Decisions Expected: April 2026
- FDA Decisions Expected: May 2026
- FDA Decisions Expected: June 2026
- FDA Decisions Expected: July 2026
- FDA Decisions Expected: August 2026
- FDA Decisions Expected: September 2026
- GLP-1
- 2024-2025
- GLP-1 Pipeline Update: November 2024
- GLP-1 Pipeline Update: November 2025
- The evolution of GLP-1s
- GLP-1 Pipeline Update: February 2025
- GLP-1 Pipeline Update: May 2025
- GLP-1 Pipeline Update: August 2025
- GLP-1 Pipeline Update: February 2026
- GLP-1 Pipeline Update: May 2026
- GLP-1 Pipeline Update: August 2026
- High Cost Therapy Profile
- 2024-2025
- High-Cost Therapy Profile: August 2024
- High-Cost Therapy Profile: June 2024
- High-Cost Therapy Profile: May
- High-Cost Therapy Profile: April
- High-Cost Therapy Profile: March
- High-Cost Therapy Profile: February
- High-Cost Therapy Profile: January
- High-Cost Therapy Profile: September 2024
- HIGH COST THERAPY PROFILE: OCT 2024
- High Cost Therapy Profile: November 2024
- High Cost Therapy Profile: December 2024
- High Cost Therapy Profile: January 2025
- High Cost Therapy Profile: February 2025
- High-Cost Therapy Profile: March 2025
- High Cost Therapy Profile: April 2025
- High-Cost Therapy Profile: May 2025
- High-Cost Therapy Profile: June 2025
- High-Cost Therapy Profile: July 2025
- High-Cost Therapy Profile: August 2025
- High-Cost Therapy Profile: September 2025
- High-Cost Therapy Profile: October 2025
- High-Cost Therapy Profile: November 2025
- High-Cost Therapy Profile: December 2025
- High-Cost Therapy Profile: January 2026
- High-Cost Therapy Profile: February 2026
- High-Cost Therapy Profile: March 2026
- Oncology Insights
- 2024-2025
- Oncology Insights: Transformative treatment for small cell lung cancer
- Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage
- Oncology Insights: October 2024
- Oncology Insights: December 2024
- Oncology Insights: 2024 Rewind
- Oncology Insights: February 2025
- Oncology Insights: March 2025
- Oncology Insights: April 2025
- Oncology Insights: May 2025
- Oncology Insights: June 2025
- Oncology Insights: July 2025
- Oncology Insights: August 2025
- Oncology Insights: September 2025
- Oncology Insights: October 2025
- Oncology Insights: November 2025
- Oncology Insights: December 2025
- Oncology Insights: January 2026
- Oncology Insights: February 2026
- Oncology Insights: March 2026
- Oncology Insights: April 2026
- Oncology Insights: May 2026
- Oncology Insights: June 2026
- Oncology Insights: July 2026
- Oncology Insights: August 2026
- Pharmacy Trend Reports
- Medicaid Pharmacy Trend Reports
- 2024 Medical Pharmacy Trend Report
- 2025 Medical Pharmacy Trend Report
- 2026 Medical Pharmacy Trend Report Part 1
- 2026 Medical Pharmacy Trend Report Part 2
- Prime Therapeutics Reports
- Fall 2024 Prime Therapeutics Report
- Spring 2024 Prime Therapeutics Report
- Summer 2024 Prime Therapeutics Report
- Spring 2025 Prime Therapeutics Report
- Summer 2025 Prime Therapeutics Report
- Fall 2025 Prime Therapeutics Report
- Spring 2026 Prime Therapeutics Report
- Summer 2026 Prime Therapeutics Report
- Quarterly Drug Approvals
- 2024-2025
- Quarterly Drug Approvals: October 2024
- Quarterly Drug Approvals: January 2025
- Quarterly Drug Approvals: April 2025
- Quarterly Drug Approvals: July 2025
- Quarterly Drug Approvals: October 2025
- Quarterly Drug Approvals: January 2026
- Quarterly Drug Approvals: April 2026
- Quarterly Drug Approvals: July 2026
- Quarterly Drug Pipeline
- 2024-2025
- Quarterly Drug Pipeline: July 2024
- Quarterly Drug Pipeline: April 2024
- Quarterly Drug Pipeline: January 2024
- Quarterly Drug Pipeline Template 2.0
- Quarterly Drug Pipeline: October 2024
- Quarterly Drug Pipeline: January 2025
- Quarterly Drug Pipeline: April 2025
- Quarterly Drug Pipeline: July 2025
- Quarterly Drug Pipeline: October 2025
- Quarterly Drug Pipeline: January 2026
- Quarterly Drug Pipeline: April 2026
- Quarterly Drug Pipeline: July 2026
- Trending Topics & Drug Approvals
- 2024-2025
- Trending Topics & Drug Approvals: May 2025
- Trending Topics & Drug Approvals: June 2025
- Trending Topics & Drug Approvals: July 2025
- Trending Topics & Drug Approvals: August 2025
- Trending Topics & Drug Approvals: September 2025
- Trending Topics & Drug Approvals: November 2025
- Trending Topics & Drug Approvals: December 2025
- Trending Topics & Drug Approvals: January 2026
- Trending Topics & Drug Approvals: February 2026
- Trending Topics & Drug Approvals: March 2026
- Trending Topics & Drug Approvals: April 2026
- Trending Topics & Drug Approvals: May 2026
- Trending Topics & Drug Approvals: June 2026
- Trending Topics & Drug Approvals: July 2026
- Trending Topics & Drug Approvals: August 2026
- Virtual reality: An emerging paradigm in health care
- Weight management: A holistic journey
- Research
- Compliance / Legal
Prime Therapeutics earns top score on Human Rights Campaign Foundation’s Corporate Equality Index
Company’s 100 score reflects its sustained commitment to LGBTQ+ inclusion across policies, benefits and culture
Every employee deserves to feel they belong at work, and for LGBTQ+ professionals, that sense of safety and inclusion often depends on more than a job description. Policies that protect, benefits that include and daily actions that affirm identity help make career growth possible. That’s the bar the Human Rights Campaign Foundation’s (HRC) Corporate Equality Index (CEI) — an annual benchmark that rates how well employers create and maintain an inclusive workplace for LGBTQ+ people sets.
This year, Prime Therapeutics (Prime) again met HRC’s full set of standards for LGBTQ+ inclusive workplaces to earn a perfect score of 100 and the Equality 100: Leader in LGBTQ+ Workplace Inclusion designation. It’s Prime’s third time receiving a top CEI score (following 2022 and 2025), signaling ongoing strong adoption of inclusivity initiatives.
“At Prime, inclusion is foundational to how we support our people and serve our members and clients,” said Erin Feigal, chief human resources officer for Prime. “Achieving a top CEI score for the third time reflects sustained, organization-wide work — from equitable benefits and inclusive policies to active employee resource groups — that helps all employees feel seen, supported and able to thrive.”
“Our goal is to create a workplace where everyone can show up as their authentic selves, which requires thoughtful action, not just intention,” added Zabrina Watkins, diversity, equity and inclusion program director. “Earning 100 again on the CEI reinforces that we’re making steady progress and building a culture where all employees feel supported and welcomed.”
For Prime, LGBTQ+ inclusion isn’t just values‑aligned; it strengthens Prime’s ability to attract talent, deliver for health plans and employers, and model a culture its stakeholders expect.
The CEI assesses four areas: non‑discrimination, equitable benefits, inclusive culture and social responsibility. Prime’s approach aligns policy, benefits and culture across these pillars through enterprise governance and human resources (HR) partnerships, enabling consistent application across a national workforce and reinforcing year‑over‑year progress.
What’s behind Prime’s score
Prime’s score reflects programs such as transgender-inclusive health benefits; explicit policy protections for sexual orientation and gender identity/expression; Prime Pride employee resource group programming; and inclusive HR practices like pronoun/self-identification and family-formation benefits. These foundations help people do their best work and help others know what to expect from Prime every day.
Follow Prime’s progress on its path to create a more inclusive culture, both inside the company and with its clients and partners.
Learn about how the HRC Foundation creates impact through its programs and initiatives, working with individuals and organizations to make transformational change in the lives of LGBTQ+ people.
About Prime Therapeutics
Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit us at PrimeTherapeutics.com or follow us on LinkedIn.